BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 8357473)

  • 1. [Sublingual specific immunotherapy for rhinoconjunctivitis caused by grass pollens].
    Sabbah A; Lesellin J; Hassoun S; Sicard H; André C
    Allerg Immunol (Paris); 1993 Jun; 25(6):241-7. PubMed ID: 8357473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-blind, placebo-controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract.
    Sabbah A; Hassoun S; Le Sellin J; André C; Sicard H
    Allergy; 1994 May; 49(5):309-13. PubMed ID: 8092425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sublingual immunotherapy with a standardised grass pollen extract; a double-blind placebo-controlled study.
    Hordijk GJ; Antvelink JB; Luwema RA
    Allergol Immunopathol (Madr); 1998; 26(5):234-40. PubMed ID: 9885731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.
    Durham SR; Yang WH; Pedersen MR; Johansen N; Rak S
    J Allergy Clin Immunol; 2006 Apr; 117(4):802-9. PubMed ID: 16630937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rush immunotherapy with sublingual administration of grass allergen extract.
    Feliziani V; Marfisi RM; Parmiani S
    Allergol Immunopathol (Madr); 1993; 21(5):173-8. PubMed ID: 8160561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis.
    Frew AJ; Powell RJ; Corrigan CJ; Durham SR;
    J Allergy Clin Immunol; 2006 Feb; 117(2):319-25. PubMed ID: 16461133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Grass allergen tablet immunotherapy relieves individual seasonal eye and nasal symptoms, including nasal blockage.
    Durham SR; Riis B
    Allergy; 2007 Aug; 62(8):954-7. PubMed ID: 17620075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double-blind, placebo-controlled evaluation of grass pollen specific immunotherapy with oral drops administered sublingually or supralingually.
    Panzner P; Petrás M; Sýkora T; Lesná I
    Respir Med; 2008 Sep; 102(9):1296-304. PubMed ID: 18585908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of high dose sublingual immunotherapy in patients with rhinoconjunctivitis.
    Worm M
    Eur Ann Allergy Clin Immunol; 2006 Dec; 38(10):355-60. PubMed ID: 17274520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis.
    Didier A; Worm M; Horak F; Sussman G; de Beaumont O; Le Gall M; Melac M; Malling HJ
    J Allergy Clin Immunol; 2011 Sep; 128(3):559-66. PubMed ID: 21802126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study.
    Bufe A; Ziegler-Kirbach E; Stoeckmann E; Heidemann P; Gehlhar K; Holland-Letz T; Braun W
    Allergy; 2004 May; 59(5):498-504. PubMed ID: 15080830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective, randomized, double-blind, placebo-controlled multi-centre study on the efficacy and safety of sublingual immunotherapy (SLIT) in children with seasonal allergic rhinoconjunctivitis to grass pollen.
    Rolinck-Werninghaus C; Wolf H; Liebke C; Baars JC; Lange J; Kopp MV; Hammermann J; Leupold W; Bartels P; Gruebl A; Bauer CP; Schnitker J; Wahn U; Niggemann B
    Allergy; 2004 Dec; 59(12):1285-93. PubMed ID: 15507097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoid sublingual immunotherapy.
    Palma-Carlos AG; Santos AS; Branco-Ferreira M; Pregal AL; Palma-Carlos ML
    Eur Ann Allergy Clin Immunol; 2006 Mar; 38(3):87-9. PubMed ID: 16752693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Agreement of efficacy assessments for five-grass pollen sublingual tablet immunotherapy.
    Didier A; Melac M; Montagut A; Lhéritier-Barrand M; Tabar A; Worm M
    Allergy; 2009 Jan; 64(1):166-71. PubMed ID: 19076546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of allergen immunotherapy and drug treatment in seasonal rhinoconjunctivitis: a 3-years study.
    Giovannini M; Braccioni F; Sella G; Contoli M; Perri G; Frati F; Incorvaia C
    Eur Ann Allergy Clin Immunol; 2005 Feb; 37(2):69-71. PubMed ID: 15859367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of sublingual rush immunotherapy with grass allergen extracts. A double blind study.
    Feliziani V; Lattuada G; Parmiani S; Dall'Aglio PP
    Allergol Immunopathol (Madr); 1995; 23(5):224-30. PubMed ID: 8526180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis.
    Dahl R; Stender A; Rak S
    Allergy; 2006 Feb; 61(2):185-90. PubMed ID: 16409194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma.
    Roberts G; Hurley C; Turcanu V; Lack G
    J Allergy Clin Immunol; 2006 Feb; 117(2):263-8. PubMed ID: 16461125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sublingual immunotherapy with grass pollen is not effective in symptomatic youngsters in primary care.
    Röder E; Berger MY; Hop WC; Bernsen RM; de Groot H; Gerth van Wijk R
    J Allergy Clin Immunol; 2007 Apr; 119(4):892-8. PubMed ID: 17321581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sublingual immunotherapy in patients with allergic rhinoconjunctivitis caused by ragweed pollen.
    Skoner D; Gentile D; Bush R; Fasano MB; McLaughlin A; Esch RE
    J Allergy Clin Immunol; 2010 Mar; 125(3):660-6, 666.e1-666.e4. PubMed ID: 20153030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.